Swedish Orphan Biovitrum agrees with Fresenius Biotech to distribute Removab

31-Jan-2011 - Sweden

Swedish Orphan Biovitrum announced a Removab® distribution agreement with Fresenius Biotech. Under the agreement Swedish Orphan Biovitrum (Sobi) will distribute Removab® exclusively in 15 European countries over 7 years.

Removab® was granted marketing authorization by the European Commission in April 2009 for the treatment of malignant ascites associated with cancer  and  has been launched in Germany and Austria so far. The territories in which Sobi will distribute Removab® are Sweden, Denmark, Norway, Finland, Iceland, Poland, Czech Republic, Slovakia, Slovenia, Romania, Bulgaria, Hungary, Estonia, Latvia and Lithuania.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance